Check out your Company Bowl for anonymous work chats.
Proscia, a leading provider of digital and computational pathology solutions, and Unilabs, a leading international provider of diagnostic services, have established a strategic partnership to accelerate the adoption of artificial intelligence (AI) in routine pathology practice. Through the collaboration, Unilabs will validate the efficacy of Proscia’s computational pathology applications and deploy them into its high-throughput workflows, improving diagnostic quality and reducing turnaround times to directly benefit patients and the physicians treating them.
Proscia, a leading provider of digital and computational pathology solutions, and Ibex Medical Analytics, the pioneer in artificial intelligence (AI)-based cancer diagnostics, have entered into a strategic partnership to support pathologists in detecting prostate cancer, the second leading cause of cancer death among men in the United States. Through the collaboration, the partners will advance the use of computationally-enabled workflows leveraging AI, which drive accuracy, efficiency, and quality gains in routine pathology diagnosis.
Proscia, a leading provider of digital and computational pathology solutions, has extended its commitment as a Partner Against Cancer with the American Cancer Society (ACS) to advance the companies’ shared goal of improving patient outcomes. As a Partner Against Cancer, Proscia will continue to support the ACS Hope Lodge program, which provides free lodging for patients and their caregivers when the best hope for effective treatment may be in another city.
Proscia announced that Laboratorium Pathologie Oost-Nederland (LabPON), the first laboratory in the world to reach 100% digital pathology diagnosis, will deploy its Concentriq platform. In transitioning to Concentriq, LabPON gains added flexibility to scale its routine digital pathology operations as the total number of worldwide cancer cases continues to rise. This includes establishing the software infrastructure for later implementing computational applications leveraging artificial intelligence to further improve diagnostic quality and efficiency.
Proscia has secured $23 million in Series B funding led by Scale Venture Partners, with participation from Hitachi Ventures, the strategic corporate venture capital arm of Hitachi, Ltd., bringing its funding total to $35 million. The company will use the investment to accelerate its global growth and strengthen its position of leadership in transforming cancer research and diagnosis at a time when demand for modernizing pathology is higher than ever.
Proscia announced that NASA’s Jet Propulsion Laboratory (JPL) and the National Cancer Institute Consortium for Molecular Characterization of Screen-Detected Lesions (MCL), coordinated by Baylor College of Medicine, have deployed Proscia’s Concentriq platform to advance biomedical research on improving cancer treatment. Through this collaborative program, JPL is digitizing a repository of valuable pathology data to make it readily accessible to researchers from across the seven sites of the consortium. Researchers will use the data to unlock new insights that combat the growing challenge of overdiagnosis, which results in unnecessary treatment of cancers that would have never caused medical problems for the patient.
Proscia announced that the Joint Pathology Center (JPC), the premiere pathology reference center for the U.S. government, has selected the Concentriq® platform for a complete transformation of its pathology practice. At the center of this modernization effort, JPC will digitize its tissue archive, the world’s largest repository of human pathology specimen, to capitalize on this invaluable source of medical data. The digital repository will provide increased access to data for driving medical advances related to infectious diseases and cancer as well as accelerate the development of computational pathology applications establishing diagnosis, prognosis, and personalized therapies for patients.
Proscia has named pathology and laboratory management veteran Dr. Monica Santamaria-Fries to its executive team. In her role as Digital Transformation Officer, Dr. Santamaria-Fries will draw on her experience to guide diagnostic laboratories in the transition to digital pathology amid a rising demand for adoption.
Proscia has introduced the third generation of its Concentriq platform to help life sciences organizations accelerate the lengthy drug development process. This release includes features and enhancements that centralize pathology operations across the enterprise, bringing together multi-site teams, data, and third-party applications to unlock new insights that advance groundbreaking discoveries.
Proscia and Dutch hospital University Medical Center Utrecht (UMC Utrecht), a pioneer in the adoption of routine digital pathology, are collaborating to establish a Center of Excellence to advance the use of computational pathology in clinical practice. The Center of Excellence will validate the efficacy of Proscia’s AI applications and deploy them into high-throughput pathology workflows to drive quality and efficiency gains. In doing so, it will demonstrate best practices for the broader adoption of computational pathology amongst diagnostic laboratories.
